Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.2817
-0.0007 (-0.25%)
At close: Jan 9, 2026, 4:00 PM EST
0.2979
+0.0162 (5.75%)
After-hours: Jan 9, 2026, 7:53 PM EST
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,752,444
Market Cap
12.90M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -3 | -25.00% |
| Dec 31, 2023 | 12 | -3 | -20.00% |
| Dec 31, 2022 | 15 | 6 | 66.67% |
| Dec 31, 2021 | 9 | 0 | - |
| Dec 31, 2020 | 9 | -1 | -10.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKTX News
- 1 day ago - Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewsWire
- 2 days ago - Akari Therapeutics to Present at the 2026 Biotech Showcase - GlobeNewsWire
- 11 days ago - Akari Therapeutics Issues 2025 End of Year Letter to Shareholders - GlobeNewsWire
- 18 days ago - Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial - GlobeNewsWire
- 23 days ago - Akari Therapeutics Releases Virtual Investor “What This Means” Segment - GlobeNewsWire
- 25 days ago - Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - GlobeNewsWire